Clionix offer solutions to life sciences industry in diversified niche segments thanks to its partners and a balanced team of professionals.
Oncology portfolio currently is focuing on diagnosing the better ways of breast and lung cancers. On the other hand a broad range of molecular diagnostics products and respective services enable Clionix to cope with the everchanging demand of new diagnosis methodologies. Nuclear medicine division has been inheritently working on diagnostics and following up closely the new development currently Clionix is able to provide theranostics solutions including but not limited to Ga68,Lu177,Ac225 labelled compounds.
Furthermore equipment portfolio is growing with new preclinical imaging equipment as well as bioprinters. Clionix is ready to support preclinical researchers and institutions with state of the art equipment which will enable them to lead their field of research.
Services has always been a strong acumen for Clionix and within 2020 Clionix is still in a perfect position to provide unit dose radioharmacy,pharmaceutical manufacturing plant setup,new product development and scale up support as well as regulatory pathway design.